Updates are available Correction dated 2021-11-08

Article History

Received: 25 August 2021

Accepted: 3 October 2021

First Online: 11 October 2021

Change Date: 8 November 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10637-021-01198-z

Declarations

:

: The Shizuoka Cancer Center Institutional Review Board (IRB) approved this study (IRB number: J2020-85–2020-1–3), and informed consent was obtained from all patients in writing.

: Ari Nishimura reports personal fees from Ono Pharmaceutical. Akira Ono reports personal fees from AstraZeneca KK, Chugai Pharmaceutical, Ono Pharmaceutical, and MSD. Kazushige Wakuda reports grants and personal fees from Chugai Pharmaceutical, Ltd., personal fees from Taiho Pharmaceutical, personal fees from Boehringer Ingelheim, personal fees from Eli Lilly K.K., personal fees from Ono Pharmaceutical, personal fees from MSD, grants and personal fees from AstraZeneca, grants from Novartis Pharma, grants from Abbvie. Nobuaki Mamesaya reports personal fees from AstraZeneca KK, Pfizer Japan, Inc., personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Boehringer Ingelheim, personal fees from MSD K.K., personal fees from Taiho Pharmaceutical, personal fees from Ono Pharmaceutical. Shota Omori reports personal fees from Chugai Pharmaceutical, personal fees from Ono Pharmaceutical, personal fees from Taiho Pharmaceutical, personal fees from Daiichi Sankyo pharmaceutical, personal fees from Amgen, personal fees from AstraZeneca, personal fees from Novartis Pharma, outside the submitted work. HIrotsugu Kenmotsu reports grants and personal fees from Chugai Pharmaceutical, personal fees from Ono Pharmaceutical, personal fees from Boehringer Ingelheim, personal fees from Eli Lilly, personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Bristol-Myers Squibb, personal fees from MSD, grants and personal fees from Novartis Pharma, grants and personal fees from Daiichi-Sankyo pharmaceutical, grants and personal fees from AstraZeneca, personal fees from Pfizer, personal fees from Taiho Pharma. Dr. Naito reports grants from Ono Pharmaceutical, grants from Pfizer US, grants from Mochida Pharmaceutical. Haruyasu Murakami reports grants and personal fees from AstraZeneca, grants and personal fees from Chugai pharma, grants and personal fees from Takeda, grants and personal fees from Daiichi Sankyo, grants from Abbvie, grants from IQvia, personal fees from Ono Pharmaceutical, personal fees from Bristol-Myers Squibb Japan, personal fees from MSD, personal fees from Pfizer, personal fees from Novartis, personal fees from Lilly Japan, personal fees from Taiho Pharmaceutical. Hideyuki Harada reports personal fees from Daiichi Sankyo pharmaceutical, personal fees from AstraZeneca pharmaceutical, personal fees from Brain lab, personal fees from Chugai pharmaceutical, grants from Japan Agency for Medical Research and Development, grants from The National Cancer Center Research and Development fund, personal fees from Novartis pharmaceutical co., grants from Health, Labor and Welfare Science Research Grant, personal fees from Eli Lilly Japan K.K., personal fees from Pfizer Japan. Toshiaki Takahashi reports grants and personal fees from AstraZeneca KK, Pfizer Japan, grants and personal fees from Eli Lilly Japan K.K., grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Ono Pharmaceutical, grants and personal fees from MSD, grants and personal fees from Boehringer Ingelheim Japan, Inc., grants and personal fees from Pfizer Japan, personal fees from Roche Diagnostics K.K. For the remaining authors no conflict interested are declared.